Ernexa Therapeutics Inc. (ERNA)
NASDAQ: ERNA · Real-Time Price · USD
0.307
+0.009 (2.89%)
At close: Mar 4, 2026, 4:00 PM EST
0.292
-0.014 (-4.70%)
Pre-market: Mar 5, 2026, 5:32 AM EST
Ernexa Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2018 |
| Revenue | 0 | 0.58 | 0.07 | - | - | - | Upgrade
|
| Revenue Growth (YoY) | -99.83% | 755.88% | - | - | - | - | Upgrade
|
| Cost of Revenue | - | 0.1 | 0.24 | - | - | - | Upgrade
|
| Gross Profit | 0 | 0.49 | -0.17 | - | - | - | Upgrade
|
| Selling, General & Admin | 5.48 | 13.32 | 14.77 | 16.84 | 14.72 | 3.3 | Upgrade
|
| Research & Development | 4.45 | 4.41 | 5.73 | 10.39 | 12.71 | 3.95 | Upgrade
|
| Operating Expenses | 9.92 | 17.74 | 20.51 | 27.23 | 27.43 | 7.25 | Upgrade
|
| Operating Income | -9.92 | -17.25 | -20.68 | -27.23 | -27.43 | -7.25 | Upgrade
|
| Interest Expense | -3.48 | -6.75 | -0.61 | -0.03 | -0.07 | -0.04 | Upgrade
|
| Interest & Investment Income | 0.29 | 0.25 | 0.14 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | -6.94 | -0.98 | -0.12 | 9.89 | -0 | - | Upgrade
|
| EBT Excluding Unusual Items | -20.06 | -24.73 | -21.27 | -17.36 | -27.5 | -7.29 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | - | -5.77 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | -0.06 | -0.94 | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | -9.65 | - | Upgrade
|
| Other Unusual Items | 1.75 | -19.78 | 0.12 | -0.24 | 0.97 | - | Upgrade
|
| Pretax Income | -18.31 | -44.51 | -21.67 | -24.53 | -122.48 | -7.29 | Upgrade
|
| Income Tax Expense | 0.03 | 0.03 | -0 | 0.05 | 0.06 | - | Upgrade
|
| Net Income | -18.34 | -44.54 | -21.67 | -24.58 | -122.55 | -7.29 | Upgrade
|
| Preferred Dividends & Other Adjustments | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | - | Upgrade
|
| Net Income to Common | -18.36 | -44.56 | -21.68 | -24.6 | -122.56 | -7.29 | Upgrade
|
| Shares Outstanding (Basic) | 5 | 1 | 0 | 0 | 0 | 0 | Upgrade
|
| Shares Outstanding (Diluted) | 5 | 1 | 0 | 0 | 0 | 0 | Upgrade
|
| Shares Change (YoY) | 1252.42% | 156.81% | 74.17% | 40.92% | 146.19% | - | Upgrade
|
| EPS (Basic) | -3.76 | -48.97 | -61.21 | -120.92 | -849.15 | -124.36 | Upgrade
|
| EPS (Diluted) | -3.76 | -48.97 | -61.21 | -120.92 | -849.15 | -124.36 | Upgrade
|
| Free Cash Flow | -9.44 | -16.21 | -20.43 | -21.27 | -23.64 | -8.14 | Upgrade
|
| Free Cash Flow Per Share | -1.93 | -17.81 | -57.66 | -104.59 | -163.80 | -138.84 | Upgrade
|
| Gross Margin | 100.00% | 83.50% | -247.06% | - | - | - | Upgrade
|
| Operating Margin | -992200.00% | -2963.92% | -30404.41% | - | - | - | Upgrade
|
| Profit Margin | -1835700.00% | -7655.50% | -31888.23% | - | - | - | Upgrade
|
| Free Cash Flow Margin | -943600.00% | -2784.36% | -30039.71% | - | - | - | Upgrade
|
| EBITDA | -9.85 | -17.11 | -20.59 | -27.07 | -27.31 | -7.15 | Upgrade
|
| D&A For EBITDA | 0.07 | 0.14 | 0.08 | 0.16 | 0.12 | 0.1 | Upgrade
|
| EBIT | -9.92 | -17.25 | -20.68 | -27.23 | -27.43 | -7.25 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.